A Phase 1/1b Multiple Cohort Trial of ALTA3263 in Patients With Advanced Solid Tumors With KRAS Mutations

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT06835569

Title field or adapter rule

{'original_value': 'A Phase 1/1b Multiple Cohort Trial of ALTA3263 in Patients With Advanced Solid Tumors With KRAS Mutations', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:22.054483+00:00

Published At

2026-10-26T00:00:00+00:00

Record Updated At

2026-10-26

Source Retrieved At

2026-10-31T22:17:25.750886+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Cancer", "PDAC - Pancreatic Ductal Adenocarcinoma", "NSCLC (Non-small Cell Lung Cancer)", "CRC (Colorectal Cancer)", "Advanced Solid Tumors"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-26", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT06835569"

protocolSection.identificationModule.officialTitle

"A Phase 1/1b Multiple Cohort Trial of ALTA3263 in Patients With Advanced Solid Tumors With KRAS Mutations"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE1"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Cancer (protocolSection.conditionsModule.conditions)
• PDAC - Pancreatic Ductal Adenocarcinoma (protocolSection.conditionsModule.conditions)
• NSCLC (Non-small Cell Lung Cancer) (protocolSection.conditionsModule.conditions)
• CRC (Colorectal Cancer) (protocolSection.conditionsModule.conditions)
• Advanced Solid Tumors (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['ALTA3263 Midazolam DDI Substudy', 'ALTA3263 in combination with GnP', 'ALTA3263 in combination with GnP plus cetuximab', 'ALTA3263 in combination with cetuximab', 'ALTA3263 in combination with mFOLFIRINOX', 'ALTA3263 in combination with mFOLFIRINOX plus cetuximab', 'ALTA3263 in combination with mFOLFOX6 plus cetuximab', 'ALTA3263 in combination with pembrolizumab', 'ALTA3263 in combination with pembrolizumab plus chemotherapy', 'ALTA3263 monotherapy'], 'description': 'Oral ALTA3263 tablets will be administered at a protocol-defined dose', 'name': 'ALTA3263', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['ALTA3263 in combination with GnP plus cetuximab', 'ALTA3263 in combination with cetuximab', 'ALTA3263 in combination with mFOLFIRINOX plus cetuximab', 'ALTA3263 in combination with mFOLFOX6 plus cetuximab'], 'description': 'Cetuximab injection for IV use will be administered at a protocol-defined dose', 'name': 'cetuximab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['ALTA3263 in combination with mFOLFOX6 plus cetuximab'], 'description': 'modified folinic acid (leucovorin), fluorouracil, and oxaliplatin will be administered at a protocol-defined dose', 'name': 'mFOLFOX6', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['ALTA3263 in combination with pembrolizumab', 'ALTA3263 in combination with pembrolizumab plus chemotherapy'], 'description': 'Pembrolizumab injection for IV use will be administered at a protocol-defined dose', 'name': 'Pembrolizumab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['ALTA3263 in combination with pembrolizumab plus chemotherapy'], 'description': 'Pemetrexed and carboplatin/cisplatin injection for IV use will be administered at a protocol-defined dose', 'name': 'Pemetrexed + Cisplatin /Carboplatin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['ALTA3263 in combination with mFOLFIRINOX', 'ALTA3263 in combination with mFOLFIRINOX plus cetuximab'], 'description': 'modified folinic acid (leucovorin), fluorouracil, irinotecan, and oxaliplatin will be administered at a protocol-defined dose', 'name': 'mFOLFIRINOX', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['ALTA3263 in combination with GnP', 'ALTA3263 in combination with GnP plus cetuximab'], 'description': 'gemcitabine and albumin-bound paclitaxel will be administered at a protocol-defined dose', 'name': 'GnP', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['ALTA3263 Midazolam DDI Substudy'], 'description': 'Oral midazolam will be administered at a protocol-defined dose', 'name': 'Midazolam', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• ALTA3263 (protocolSection.armsInterventionsModule.interventions[].name)
• cetuximab (protocolSection.armsInterventionsModule.interventions[].name)
• mFOLFOX6 (protocolSection.armsInterventionsModule.interventions[].name)
• Pembrolizumab (protocolSection.armsInterventionsModule.interventions[].name)
• Pemetrexed + Cisplatin /Carboplatin (protocolSection.armsInterventionsModule.interventions[].name)
• mFOLFIRINOX (protocolSection.armsInterventionsModule.interventions[].name)
• GnP (protocolSection.armsInterventionsModule.interventions[].name)
• Midazolam (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.